Sunshine Biopharma (SBFM)
NASDAQ:SBFM
Want to see SBFM full AI Analyst Report?
SBFM Stock Chart & Stats
$1.23
$0.01(0.82%)
At close: 4:00 PM EST
$1.23
$0.01(0.82%)
Day’s Range― - ―
52-Week Range$0.95 - $2.43
Previous CloseN/A
Volume1.45K
Average Volume (3M)1.09M
Market Cap
$5.18M
Enterprise Value-$3.14M
Total Cash (Recent Filing)$9.12M
Total Debt (Recent Filing)$812.42K
Price to Earnings (P/E)―
Beta1.59
Next Earnings
May 13, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.89
Shares Outstanding4,905,945
10 Day Avg. Volume3,175,467
30 Day Avg. Volume1,091,586
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.14
P/FCF Ratio-0.93
Enterprise Value/Market Cap-0.61
Enterprise Value/Revenue-0.09
Enterprise Value/Gross Profit-0.26
Enterprise Value/Ebitda0.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$50.00M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageReported zero debt in 2025 and modest leverage historically reduce bankruptcy and refinancing risk, giving the company durable financial flexibility. This lowers fixed financing costs, improving the company's ability to invest in commercialization or weather continued operating losses without immediate solvency pressure.
Reasonable Gross MarginsSustained gross margins around 31–39% indicate the core product economics and third‑party manufacturing model can generate healthy unit profitability. Over months, such margins provide a structural cushion to absorb SG&A and R&D and make profitability achievable if operating expenses are controlled or revenue mix improves.
Established Revenue BaseHistorical scaling of revenue and a solid 2024–2025 top line create a durable commercial foundation—ongoing product sales, distribution relationships and channel access—that management can leverage to pursue margin improvement, incremental launches, or in‑licensed products over the coming months.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow from 2020–2025 indicates the company is not self‑funding and must rely on external capital. Over a 2–6 month horizon this structural cash burn raises dilution and financing‑risk concerns and limits the firm's ability to sustainably invest in commercialization or R&D without new funding.
Ongoing Operating LossesRepeated operating and net losses with -15% to -19% margins show the business has not yet achieved operating leverage. This structural unprofitability reduces retained capital for reinvestment, depresses returns on equity, and implies the firm needs either sustained revenue expansion or meaningful cost restructuring to reach durable profitability.
Concentrated Shareholder Control / Governance RiskMajority voting control by the CEO and an approved potential reverse split create durable governance concentration. Such control can enable rapid structural decisions (share consolidation, financing terms) that may disadvantage minority holders and elevate execution risk, complicating governance oversight and long‑term strategic alignment.
Sunshine Biopharma News
SBFM FAQ
What was Sunshine Biopharma’s price range in the past 12 months?
Sunshine Biopharma lowest stock price was $0.95 and its highest was $2.43 in the past 12 months.
What is Sunshine Biopharma’s market cap?
Sunshine Biopharma’s market cap is $5.18M.
When is Sunshine Biopharma’s upcoming earnings report date?
Sunshine Biopharma’s upcoming earnings report date is May 13, 2026 which is in 8 days.
How were Sunshine Biopharma’s earnings last quarter?
Sunshine Biopharma released its earnings results on Nov 11, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.06.
Is Sunshine Biopharma overvalued?
According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued.
Does Sunshine Biopharma pay dividends?
Sunshine Biopharma does not currently pay dividends.
What is Sunshine Biopharma’s EPS estimate?
Sunshine Biopharma’s EPS estimate is -0.16.
How many shares outstanding does Sunshine Biopharma have?
Sunshine Biopharma has 4,905,945 shares outstanding.
What happened to Sunshine Biopharma’s price movement after its last earnings report?
Sunshine Biopharma reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went up 1.744%.
Which hedge fund is a major shareholder of Sunshine Biopharma?
Currently, no hedge funds are holding shares in SBFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sunshine Biopharma
Sunshine Biopharma (SBFM) is a biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer and other serious diseases. The company operates within the biotechnology sector, where it specializes in drug discovery and development, particularly in the areas of oncology and related treatments. Sunshine Biopharma's core products include a pipeline of drug candidates that address unmet medical needs, leveraging advanced technologies to enhance therapeutic efficacy and patient outcomes.
Technical Analysis
Sonoma Pharmaceuticals
―
―
cbdMD
―
IM Cannabis Corp
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
2.04% Insiders
<0.01% Other Institutional Investors
97.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---